Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3062956 | 0.97 | ALDH1A1 (0.38) | ALDH1A1TSHRMEN1CYP1A2THRB | |
| SCHEMBL2599668 | 0.83 | ALDH1A1 (0.33) | ALDH1A1TSHRMEN1CYP1A2THRB | |
| SCHEMBL105436 | 0.83 | FFAR3 (0.39) | ALDH1A1TSHRMEN1CYP1A2THRB | |
| SCHEMBL28314797 | 0.80 | FFAR3 (0.37) | ALDH1A1TSHRMEN1CYP1A2THRB | |
| SCHEMBL28315783 | 0.80 | FFAR3 (0.37) | ALDH1A1TSHRMEN1CYP1A2THRB | |
| SCHEMBL51201 | 0.80 | FFAR3 (0.41) | ALDH1A1TSHRMEN1CYP1A2THRB | |
| SCHEMBL9307815 | 0.80 | MEN1 (0.31) | ALDH1A1MEN1CYP1A2THRBKMT2A | |
| SCHEMBL104624 | 0.77 | FFAR3 (0.39) | ALDH1A1TSHRMEN1CYP1A2THRB | |
| SCHEMBL17818653 | 0.77 | FFAR3 (0.39) | ALDH1A1TSHRMEN1CYP1A2THRB | |
| Hydrochloric Acid SCHEMBL8053454 | 0.77 | FFAR3 (0.39) | ALDH1A1TSHRMEN1CYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107602809-A | High-solid content water-based polyurethane dispersion liquid a kind of while based on aminocarboxylate and sulfamate | 温州大学 | 2018-01-19 | — | — | CN | claimed |
| US-4902819-A | Preparation of sodium diethyl oxalacetate | HOECHST CELANESE CORPORATION (US) | 1990-02-20 | — | — | US | claimed |
| EP-4680608-A1 | 2,6-DIHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE DERIVATIVES AS ANTI-MALARIAL AGENTS | MMV Medicines for Malaria Venture (CH) | 2026-01-21 | — | — | EP | disclosed |
| US-20240208990-A1 | SPIRO-COMPOUNDS AND COMPOSITIONS INCLUDING THE SAME | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2024-06-27 | — | — | US | disclosed |
| EP-4347602-A1 | SPIRO-COMPOUNDS AND COMPOSITIONS INCLUDING THE SAME | Solventum Intellectual Properties Company (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022248947-A1 | SPIRO-COMPOUNDS AND COMPOSITIONS INCLUDING THE SAME | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-3359541-B1 | N-SULFONYLATED PYRAZOLO[3,4-B]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE OVERSEAS SARL (LU) | 2020-08-05 | — | — | EP | disclosed |
| CN-107635975-B | DGAT2 inhibitors | 伊莱利利公司 | 2020-07-24 | — | — | CN | disclosed |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | ABBVIE S.Á.R.L. (LU) | 2020-05-12 | — | — | US | disclosed |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | ABBVIE SARL (LU) | 2019-10-31 | — | — | US | disclosed |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | ABBVIE SARL (LU) | 2019-07-04 | — | — | US | disclosed |
| US-5556987-A | Process for producing pyrazolecarboxamide derivative | FUJI PHOTO FILM CO., LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| WO-1994022866-A1 | PYRAZOLOQUINAZOLONE DERIVATIVES AS NEUROTROPHIC AGENTS | WARNER-LAMBERT COMPANY (US) | 1994-10-13 | — | — | WO | disclosed |
| US-5342942-A | Pyrazoloquinazolone derivatives as neurotrophic agents | WARNER-LAMBERT COMPANY (US) | 1994-08-30 | — | — | US | disclosed |
| US-5252560-A | Cyclic imide derivatives, compositions and use | GLAXO INC. (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0520573-A1 | Cyclic imide derivatives | GLAXO INC. (US) | 1992-12-30 | — | — | EP | disclosed |
| US-4737585-A | Process for the preparation of sodium amoxycillin | ANTIBIOTICOS S.A. (ES) | 1988-04-12 | — | — | US | disclosed |
| EP-0220925-A1 | A process for the preparation of sodium amoxycillin | Antibioticos, S.A. (ES) | 1987-05-06 | — | — | EP | disclosed |
| EP-0125276-A1 | NEW CHELATE FORMING BISQUINOLINE COMPOUNDS AND PROCESSES FOR RECOVERING METALS | HÖGBERG, Sverker (SE) | 1984-11-21 | — | — | EP | disclosed |
| WO-1984001946-A1 | NEW CHELATE FORMING BISQUINOLINE COMPOUNDS AND PROCESSES FOR RECOVERING METALS | HOEGBERG SVERKER | 1984-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208990-A1 | SPIRO-COMPOUNDS AND COMPOSITIONS INCLUDING THE SAME | REN, PKD1, SAV1 | ALDH1A1 219/4885TSHR 988/4885MEN1 74/4885 |
| US-20190330207-A1 | N-Sulfonylated-Pyrazolo[3,4-b]Pyridin-6-Carboxamides and Method of Use | CFTR, CHRM3, P2RY1 | ALDH1A1 3177/4885TSHR 230/4885MEN1 2692/4885 |
| US-20190202823-A1 | N-SULFONYLATED PYRAZOLO[3,4-b]PYRIDIN-6-CARBOXAMIDES AND METHOD OF USE | CFTR, P2RY1, P2RX5 | ALDH1A1 3001/4885TSHR 210/4885MEN1 2496/4885 |
| US-10647717-B2 | N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | CFTR, CHRM3, P2RY1 | ALDH1A1 3177/4885TSHR 230/4885MEN1 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.